Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma.
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...
Bristol-Myers Squibb Company announced positive results from CheckMate -037, a Phase III randomized, controlled open-label study of Opdivo (nivolumab), an...
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy...
Areas covered: This is a comprehensive review of the literature on the role of pembrolizumab in melanoma.
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase III study evaluating nivolumab versus dacarbazine (DTIC) (CHECKMATE 066) in...
BMS announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously...